IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
Published: 25 Jun 2020
Views: 621
Prof Philippe Moreau - University of Nantes, Nantes, France
Prof Philippe Moreau speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses the IKEMA trial which looked at carfilzomib and dexamethasone vs carfilzomib and dexamethasone plus isatuximab in relapsed/refractory multiple myeloma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Related Videos
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
